Sam Brusco, Associate Editor10.05.23
IR-MED, an Israel-based developer of a non-invasive, artificial intelligence (AI)-driven spectrographic technology platform, revealed Tzur Di-Cori will take the company’s helm as CEO beginning October 15.
Di-Cori will succeed Oded Bashan, who is currently chairman and CEO. He will continue as IR-MED’s chairman.
Di-Cori has over 30 years of experience in executive roles at medical device and high-tech companies. He’s been co-founder and owner of NatureIM—a company developing peptide-derived materials—since 2023. From 2020-2023, he was CEO of air purification technology firm DUSMIT, and co-founder/CEO of medical cannabis delivery company Veoli from 2017-2020.
His medical device experience includes the CEO role at robotic physical therapy firm Motorika Medical, as well as president and CEO of LifeWatch Technologies—which was acquired by Philips in 2020 when it bought BioTelemetry.
“Tzur is a seasoned and agile leader who has led growth and success at multiple healthcare companies,” Bashan told the press. “His experience at LifeWatch in developing and commercializing technologies that aid in the early detection of health conditions is particularly pertinent to our mission at IR-MED.”
IR-MED’s non-invasive, spectrographic analysis platform reportedly helps healthcare professionals detect, measure, and monitor different molecules in blood, human tissue, and body fluids. Its PressureSafe handheld optical monitor is its first product under development. The device aims to support early pressure injury detection in skin and underlying tissue, regardless of skin tone.
PressureSafe, according to IR-MED, is currently amid usability studies at multiple medical centers.
“IR-MED has a tremendous opportunity to change the paradigm of detection and timely treatment of a range of health conditions, with pressure injuries alone having the potential to significantly improve care for patients and economics for providers while addressing healthcare equity,” added Di-Cori. “I’m very excited join IR-MED and to propel the company into rapid deployment of its platform technology.”
Di-Cori will succeed Oded Bashan, who is currently chairman and CEO. He will continue as IR-MED’s chairman.
Di-Cori has over 30 years of experience in executive roles at medical device and high-tech companies. He’s been co-founder and owner of NatureIM—a company developing peptide-derived materials—since 2023. From 2020-2023, he was CEO of air purification technology firm DUSMIT, and co-founder/CEO of medical cannabis delivery company Veoli from 2017-2020.
His medical device experience includes the CEO role at robotic physical therapy firm Motorika Medical, as well as president and CEO of LifeWatch Technologies—which was acquired by Philips in 2020 when it bought BioTelemetry.
“Tzur is a seasoned and agile leader who has led growth and success at multiple healthcare companies,” Bashan told the press. “His experience at LifeWatch in developing and commercializing technologies that aid in the early detection of health conditions is particularly pertinent to our mission at IR-MED.”
IR-MED’s non-invasive, spectrographic analysis platform reportedly helps healthcare professionals detect, measure, and monitor different molecules in blood, human tissue, and body fluids. Its PressureSafe handheld optical monitor is its first product under development. The device aims to support early pressure injury detection in skin and underlying tissue, regardless of skin tone.
PressureSafe, according to IR-MED, is currently amid usability studies at multiple medical centers.
“IR-MED has a tremendous opportunity to change the paradigm of detection and timely treatment of a range of health conditions, with pressure injuries alone having the potential to significantly improve care for patients and economics for providers while addressing healthcare equity,” added Di-Cori. “I’m very excited join IR-MED and to propel the company into rapid deployment of its platform technology.”